GSK acquires Hungarian vaccine facility
GlaxoSmithKline Biologicals (GSK Bio) has acquired the vaccine manufacturing facilities, in Godollo, Hungary, of Human Serum and Medicine Manufacturing, an affiliate of Teva Pharmaceutical Industries.
The new company will be called GlaxoSmithKline Biologicals KFt, and brings GSK Bio significantly increased capacity of key vaccine antigens for diphtheria and tetanus toxoids and whole-cell pertussis (whooping-cough). 'The acquisition of Human's vaccines facilities brings us a very high quality facility and team, plus a significantly increased supply of these key antigens,' said Jean Stephenne, president and general manager of GSK Bio.
GSK Bio teams of researchers are actively working on future vaccines against malaria, HIV, TB, S. pnuemoniae, rotavirus and many other diseases of global importance.